Please login to the form below

Not currently logged in
Email:
Password:

achondroplasia

This page shows the latest achondroplasia news and features for those working in and with pharma, biotech and healthcare.

BioMarin eyes 2019 FDA filing for haemophilia A gene therapy

BioMarin eyes 2019 FDA filing for haemophilia A gene therapy

During the update, BioMarin also laid out its expectations for vosoritide, a drug for short stature in children with achondroplasia in a phase 3 trial due to read out before the ... Achondroplasia is the leading cause of short stature, and is caused by

Latest news

  • BioMarin drug boosts growth in children with dwarfism BioMarin drug boosts growth in children with dwarfism

    The small study in children with achondroplasia - the most common form of dwarfism - showed that children treated with the highest dose of BMN 111 (vosoritide) grew 6cm in six months, while ... The results suggest vosoritide could a new treatment option

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics